Soligenix Inc. (SNGX)’s Financial Results Comparing With Avid Bioservices Inc. (NASDAQ:CDMO)

As Biotechnology businesses, Soligenix Inc. (NASDAQ:SNGX) and Avid Bioservices Inc. (NASDAQ:CDMO), are affected by compare. This especially applies to their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Soligenix Inc. 1 -3.89 16.62M -0.58 0.00
Avid Bioservices Inc. 7 -2.42 42.71M -0.20 0.00

Table 1 showcases the gross revenue, earnings per share and valuation of Soligenix Inc. and Avid Bioservices Inc.


Table 2 has Soligenix Inc. and Avid Bioservices Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Soligenix Inc. 1,211,546,872.72% -214.6% -102.2%
Avid Bioservices Inc. 621,688,500.73% 0% 0%

Risk and Volatility

Soligenix Inc. has a beta of 1.26 and its 26.00% more volatile than Standard & Poor’s 500. Avid Bioservices Inc.’s 2.68 beta is the reason why it is 168.00% more volatile than Standard & Poor’s 500.


The Current Ratio and a Quick Ratio of Soligenix Inc. are 1.4 and 1.4. Competitively, Avid Bioservices Inc. has 1.8 and 1.5 for Current and Quick Ratio. Avid Bioservices Inc.’s better ability to pay short and long-term obligations than Soligenix Inc.

Analyst Ratings

The following table given below contains the ratings and recommendations for Soligenix Inc. and Avid Bioservices Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Soligenix Inc. 0 0 0 0.00
Avid Bioservices Inc. 0 0 2 3.00

Meanwhile, Avid Bioservices Inc.’s average target price is $10.5, while its potential upside is 60.55%.

Insider and Institutional Ownership

Institutional investors held 22.4% of Soligenix Inc. shares and 54.8% of Avid Bioservices Inc. shares. Soligenix Inc.’s share held by insiders are 12.6%. Insiders Comparatively, held 0.1% of Avid Bioservices Inc. shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Soligenix Inc. 18% 19.8% 26.2% 68.57% 21.65% 37.21%
Avid Bioservices Inc. 5.08% 13.31% 11.13% 44.39% 11.13% 41.22%

For the past year Soligenix Inc.’s stock price has smaller growth than Avid Bioservices Inc.


Avid Bioservices Inc. beats Soligenix Inc. on 9 of the 11 factors.

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates through two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric CrohnÂ’s disease and acute radiation enteritis. This segment also offers SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer. The Vaccines/BioDefense segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase IB clinical trial for the treatment of vaccine against ricin toxin poisoning; VeloThrax, an anthrax vaccine candidate; OrbeShield, a GI acute radiation syndrome (GI ARS) therapeutic candidate, which is in pre-clinical stage to treat therapeutics against GI ARS; and SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of melioidosis. Its vaccines are supported by its ThermoVax, a heat stabilization technology. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was founded in 1987 and is headquartered in Princeton, New Jersey.

Avid Bioservices, Inc., a biologics contract development and manufacturing company, focuses on the development and current Good Manufacturing Practices (cGMP) manufacture of biopharmaceutical products derived from mammalian cell culture. It provides a range of process development, cGMP clinical, and commercial manufacturing services for the biotechnology and biopharmaceutical industries. The company produces monoclonal antibodies and recombinant proteins in batch, fed-batch, and perfusion modes; and offers services, including cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission, and support. It also provides various process development services, such as cell line development and optimization, cell culture and feed optimization, analytical methods development, and product characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was founded in 1981 and is headquartered in Tustin, California.